SAN DIEGO, CALIFORNIA — March 4, 2026 — Leads & Copy — Ensysce Biosciences, Inc. (NASDAQ:ENSC) held its live “Ask Me Anything” (AMA) series March 4, reinforcing the company’s commitment to transparency and open dialogue.
A replay of the AMA is available on Ensysce’s website. The clinical-stage pharmaceutical company is focused on developing next-generation pain and central nervous system therapeutics designed to minimize the risk of abuse and overdose.
During the AMA, Ensysce CEO Dr. Lynn Kirkpatrick addressed shareholders and followers, discussing Phase 3 execution, timeline visibility, capital discipline, shareholder alignment, strategic priorities, and long-term value creation. The event resulted in questions arranged under three topics.
Dr. Kirkpatrick stated the AMA session was an opportunity to engage with stakeholders and reinforce the strategic clarity behind the company’s PF614 program. She added that Ensysce believes in the commercial potential for PF614 and that the company is positioning the program to address unmet needs. Dr. Kirkpatrick said the company remains focused on execution and transparent communication as it advances these programs toward milestones.
AMA key highlights included:
- PF614-301 timeline sequencing
- Efforts to reduce clinical and regulatory uncertainty
- PF614, PF614-MPAR & ADHD pipeline prioritization
- Potential PF614 commercial opportunities
Individuals who were unable to have their questions answered are encouraged to reach out to investor relations at ENSC@mzgroup.us for future opportunities.
Ensysce Biosciences is focused on disrupting the analgesic landscape by introducing a new class of opioids for the treatment of severe pain. The company is developing tamper-proof treatment options for pain that minimize the risk of drug abuse and overdose, leveraging its Trypsin-Activated Abuse Protection (TAAP™) and Multi-Pill Abuse Resistance (MPAR®) platforms. Ensysce’s products are anticipated to provide safer options to treat patients suffering from severe pain and assist in preventing deaths caused by medication abuse.
Source: Ensysce Biosciences
